Babbe, …Rives, M.L. et al. (2024) Discovery of highly selective SIK1/2 inhibitors that modulate innate immune activation and suppress intestinal inflammation," Proceedings of the National Academy of Sciences of the United States of America, 121(1):e2307086120.
Wang, J., Nakafuku, K. M., Ziff, J., Gelin, C. F., Gholami, H., Thompson, A. A., Karpowich, N. K., Limon, L., Coate, H. R., Damm-Ganamet, K. L., Shih, A. Y., Grant, J. C., Côte, M., Mak, P. A., Pascual, H. A., Rives, M. L., Edwards, J. P., Venable, J. D., Venkatesan, H., Shi, Z., … Shireman, B. T. (2023). Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D). Bioorganic & medicinal chemistry letters, 96, 129492.
Stalewski, J., Shih, A. Y., Papazyan, R., Ramirez, J., Ibanez, G., Hsiao, P., Yue, Y., Yin, J., Badger, C., Wu, S., Ueki, A., Fuchs, B. C., & Rives, M. L.** (2023). pH Dependence of a GPR4 Selective Antagonist Hampers Its Therapeutic Potential. The Journal of pharmacology and experimental therapeutics, 386(1), 35–44.
** corresponding author
Thompson, A. A., Harbut, M. B., Kung, P. P., Karpowich, N. K., Branson, J. D., Grant, J. C., Hagan, D., Pascual, H. A., Bai, …, Côte, M., Gelin, C. F., Damm-Ganamet, K. L., Gholami, H., Huff, A. R., Limon, L., Lumb, K. J., Mak, P. A., … Rives, M.L., …, Allen, S. J. (2023). Identification of smallmolecule protein-protein interaction inhibitors for NKG2D. Proceedings of the National Academy of Sciences of the United States of America, 120(18), e2216342120.
Patch, R.J., Zhang, R., Edavettal, S., Macielag, M.J., Eckardt, A.J., Li, J., Rives, M.L., Edwards, W., Hinke, S.A., Qiu, X., Jian, W., Libiger, O., Zheng, S., Jeyaseelan, J., Liang, Y., Rangwala, S.M., Leonard, J.N., Hornby, P. (2022) Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists. Eur J Med Chem. Apr 4; 236:114330
Damm-Ganamet, K.*, Rives, M.L.*, Wickenden, A. and Mirzadegan, T. (2020) Employing Computational Methods for the Discovery of Novel and Selective EAAT2 Inhibitors. J Biol Chem. 295 (13): 4359-4366
* co-first author
Luke A. Miles, L.A, Hermans, S.J., Crespi, G.A.N., Gooi, J.H., Doughty, L., Nero, T.L., Markulić, J. Ebneth, A., Wroblowski, B., Oehlrich, D., Trabanco, A.A., Rives, M.L., Royaux, I., Hancock, N.C. and Parker, M.W. (2019) Small Molecule Binding to Alzheimer’s Risk Factor CD33 Promotes Aβ Phagocytosis. iScience vol. 19: 110-118
Rives, M.L.**, Rady, B., Swanson, N., Zhao, S., Qi, J., Arnoult, E., Bakaj, I., Mancini, A., Breton, B., Lee, S.P., Player, M.R., Pocai, A. (2018) GPR40-Mediated Gα12 Activation by Allosteric Full Agonists Highly Efficacious at Potentiating Glucose-Stimulated Insulin Secretion in Human Islets. Mol Pharmacol 93(6), 581-591
** corresponding author
Rives, M.L., Javitch, J.A. and Wickenden, A.D. (2017) Potentiating SLC transporter activity: Emerging drug discovery opportunities. Biochem Pharmacol. doi: 10.1016/j.bcp.2017.02.010.
Rives, M.L., Shaw, M., Zhu, B., Hinke, S.A. & Wickenden, A.D. (2016) State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281. Mol Pharmacol 90, 766-774
Jackson, V.M., Breen, D., Fortin, J.P., Liou, A., Kuzmiski, J.B., Loomis, K., Rives, M.L., Shah, B. and Carpino, P.A. (2015) Latest approaches for the treatment of obesity. Expert Opinion in Drug Discovery, 10(8):825-39.
Gassaway, M.M., Rives, M.L., Kruegel, A.C., Javitch, J.A. and Sames, D. (2014) The atypical antidepressant and neurorestorative agent tianeptine is a mu-opioid receptor agonist. Transl Psychiatry, 4: e411.
White, K.L., Scopton, A.P., Rives, M.L., Bikbulatov, R.V., Polepally, P.R., Brown, P.J., Kenakin, T.,, Javitch, J.A., Zjawiony, J.K. and Roth, B.L. (2014) Identification of novel functionally selective Kappa Opioid Receptor scaffolds. Mol Pharmacol, 85(1): 83-90.
Rives, M.L. and Javitch, J.A. (2013) Sensing conformational changes in metabotropic glutamate receptors. Proc Natl Acad Sci U S A, 110, 5742-5743.
Negri, A., Rives, M.L.,* Caspers, M., Prisinzano, T., Javitch, J.A. and Filizola, M. (2013) Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening. J Chem. Inf Model., 53(3), 521–526.
* co-first author
Rives, M.L., Rossillo, M., Liu-Chen, L.Y., and Javitch, J.A. (2012) 6'-Guanidinonaltrindole (6'-GNTI) Is a G Protein-biased κ-Opioid Receptor Agonist That Inhibits Arrestin Recruitment. J. Biol. Chem., 287(32), 27050-4.
Trifilieff, P., Rives, M.L., Urizar, E., Vishwasrao, H., Castrillon, J., Gullberg, M., Nyström, E., Kandel, E. and Javitch, J.A. (2011) Detection of endogenous dopamine D2- adenosine A2A receptor complexes ex vivo by proximity ligation assay. Biotechniques, 51(2), 111-8.
Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., Bazin, H., Bourrier, E., Lamarque, L., Breton, C., Rives, M.L., Newman, A., Javitch, J., Trinquet, E., Manning, M., Pin, J.P., Mouillac, B. and Durroux, T. (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat Chem Biol, 6, 587-594.
Prezeau, L., Rives, M.L., Comps-Agrar, L., Maurel, D., Kniazeff, J., Pin, J.P. (2010) Functional crosstalk between GPCRs: with or without oligomerization. Curr Opin Pharmacol. 10(1):6-13.
Pin, J.P., Comps-Agrar, L., Maurel, D., Monnier, C., Rives, M.L., Trinquet, E., Kniazeff, J., Pondard, P., Prezeau, L. (2009) G-protein-coupled receptor oligomers: two or more for what? Lessons from mGlu and GABA(B) receptors. J Physiol. 587:5337-44.
Rives, M.L., Vol, C., Fukazawa, Y., Tinel, N., Trinquet, E., Ayoub, M.A., Shigemoto, R., Pin, J.P. and Prezeau, L. (2009) Crosstalk between GABA(B) and mGlu1a receptors reveals new insight into GPCR signal integration. Embo J. 28: 2195-2208.
Maurel, D., Comps-Agrar, L., Brock, C., Rives, M.L., Bourrier, E., Ayoub, M.A., Bazin, H., Tinel, N., Durroux, T., Prezeau, L., Trinquet, E. and Pin, J.P. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods, 5, 561-567.